Related Experiment Video

Updated: Jul 15, 2026

Non-restraining EEG Radiotelemetry: Epidural and Deep Intracerebral Stereotaxic EEG Electrode Placement
06:58

Non-restraining EEG Radiotelemetry: Epidural and Deep Intracerebral Stereotaxic EEG Electrode Placement

Published on: June 25, 2016

Pyridoxine induces non-specific EEG alterations in infants with therapy resistant seizures

L K Teune1, J H vd Hoeven, N M Maurits

  • 1Department of Neurology, University Medical Center Groningen, University of Groningen, The Netherlands.

Seizure
|April 6, 2007
PubMed

Insights

Pyridoxine-IV administration in infants with therapy-resistant seizures (TRS-infants) causes non-specific EEG changes. These alterations do not reliably identify pyridoxine-dependency (PD) or pyridoxine-responsiveness (PR).

Area of Science:

  • Pediatric Neurology
  • Clinical Neurophysiology

Background:

  • Infants with therapy-resistant seizures (TRS-infants) may have pyridoxine-dependency (PD) or pyridoxine-responsiveness (PR).
  • Diagnosis often involves empirical intravenous (IV) pyridoxine administration during EEG monitoring.
  • The specificity of EEG changes following pyridoxine-IV in undiagnosed TRS-infants is not well understood.

Purpose of the Study:

  • To investigate whether EEG alterations induced by pyridoxine-IV in TRS-infants are specific to PD/PR or represent non-specific responses.
  • To determine if pyridoxine-IV can be used to reliably identify PD/PR in infants.

Main Methods:

  • Studied 10 infants under 1 year of age with TRS-infants.
  • Administered intravenous pyridoxine (pyridoxine-IV) during EEG recordings.
  • Analyzed EEG amplitude and total power changes post-administration.

Main Results:

  • Pyridoxine-IV administration led to a significant decline (10-15%) in EEG amplitudes.
  • Total EEG power across frequency bands also decreased significantly at multiple electrode sites.
  • These EEG changes were observed in all infants, irrespective of PD/PR status.

Conclusions:

  • Pyridoxine-IV administration induces non-specific changes in EEG amplitude and total power in TRS-infants.
  • These non-specific EEG alterations do not reliably identify pyridoxine-dependency or pyridoxine-responsiveness.
  • Further research is needed to establish specific biomarkers for PD/PR in infants.
Abstract

More Related Videos

Microdialysis of Excitatory Amino Acids During EEG Recordings in Freely Moving Rats08:47

Microdialysis of Excitatory Amino Acids During EEG Recordings in Freely Moving Rats

Published on: November 8, 2018

Electromagnetic Source Imaging in Presurgical Evaluation of Children with Drug-Resistant Epilepsy09:57

Electromagnetic Source Imaging in Presurgical Evaluation of Children with Drug-Resistant Epilepsy

Published on: September 20, 2024

Related Concept Videos

Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...